18889881171
Kalkine 0
countryflagUS

BridgeBio Pharma Inc

Healthcare US BBIO

47.38USD
-0.31(0.65%)

Last update at 2025-07-15T16:58:00Z

Day Range

47.0048.42
LowHigh

52 Week Range

21.6244.32
LowHigh

Fundamentals

  • Previous Close 47.69
  • Market Cap5575.20M
  • Volume889027
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-509.90301M
  • Revenue TTM217.76M
  • Revenue Per Share TTM1.19
  • Gross Profit TTM 74.21M
  • Diluted EPS TTM-2.42

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -484.65200M -586.45400M -505.48800M -288.58500M -169.45100M
Minority interest 3.47M -23.91500M -56.76400M 67.52M 62.48M
Net income -493.96400M -639.29700M -483.92500M -260.43700M -130.74900M
Selling general administrative 143.19M 192.21M 145.68M 94.35M 43.59M
Selling and marketing expenses - - - - -
Gross profit 74.21M 66.60M 8.25M 38.06M -
Reconciled depreciation 6.77M 5.84M 3.09M - 0.24M
Ebit -471.87100M -579.74600M -474.48200M -266.24000M -183.22200M
Ebitda -353.67800M -539.67600M -468.83300M -279.40400M -182.97700M
Depreciation and amortization 118.19M 40.07M 5.65M -13.16400M 0.24M
Non operating income net other 107.99M 36.96M 5.65M - -
Operating income -471.87100M -579.74600M -474.48200M -266.24000M -183.66000M
Other operating expenses 546.09M 646.35M 482.73M 306.80M 183.66M
Interest expense 80.44M 46.78M 36.66M 8.77M 2.55M
Tax provision - - - - -
Interest income 7.54M 1.13M 4.01M 8.91M 2.00M
Net interest income -72.89600M -45.64500M -32.64000M 0.15M -0.54300M
Extraordinary items - - - - -
Non recurring 43.77M - - - -
Other items - - - - -
Income tax expense 9.31M 52.84M -21.56300M -28.14800M 16.76M
Total revenue 77.65M 69.72M 8.25M 40.56M 0.00000M
Total operating expenses 546.09M 646.35M 482.73M 304.30M 183.66M
Cost of revenue 3.43M 3.11M 0.00000M 2.50M -
Total other income expense net -12.78100M -6.70800M -31.00600M -22.34500M 14.75M
Discontinued operations - - - - -
Net income from continuing ops -484.65200M -586.45400M -505.48800M -288.58500M -169.45100M
Net income applicable to common shares -481.18300M -562.53900M -448.72400M -260.58700M -130.74900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 546.38M 623.04M 1012.79M 703.59M 631.68M
Intangible assets 26.32M 28.71M 44.93M - -
Earning assets - - - - -
Other current assets 24.30M 21.92M 101.34M 35.73M 22.63M
Total liab 1888.91M 1867.96M 1878.37M 595.70M 155.70M
Total stockholder equity -1354.25700M -1254.61700M -870.41400M 57.91M 408.45M
Deferred long term liab - - - - -
Other current liab 122.97M 94.36M 113.31M 5.55M 4.08M
Common stock 0.18M 0.16M 0.15M 0.12M 0.12M
Capital stock 0.18M 0.16M 0.15M 0.12M 0.12M
Retained earnings -2560.50100M -1918.14900M -1436.96600M -888.75500M -440.03100M
Other liab - 26.64M 22.07M 7.95M 3.53M
Good will - - - - -
Other assets - 140.81M 33.03M 23.93M 26.29M
Cash 375.94M 376.69M 393.77M 356.08M 363.77M
Cash and equivalents - - - - -
Total current liabilities 143.84M 117.75M 130.13M 91.85M 52.38M
Current deferred revenue 6.10M 8.16M - 75.90M 31.45M
Net debt 1363.90M 1346.88M 1332.40M 139.71M -263.98200M
Short term debt 4.13M 3.67M 4.94M 1.46M 8.00M
Short long term debt - - - 1.46M -
Short long term debt total 1739.84M 1723.56M 1726.17M 495.79M 99.79M
Other stockholder equity 1206.03M 663.70M 566.53M 946.34M 845.86M
Property plant equipment - 14.57M 45.97M 20.32M 5.62M
Total current assets 477.59M 505.20M 839.71M 642.82M 599.77M
Long term investments - 43.65M 49.15M 0.00000M 31.14M
Net tangible assets - -1284.91800M -915.34800M 59.54M 408.45M
Short term investments 58.95M 95.23M 442.89M 251.01M 182.22M
Net receivables 1.75M 17.08M 19.75M - 2.85M
Long term debt 1726.73M 1707.62M 1703.81M 475.86M 91.79M
Inventory 16.65M 37.93M -68.89700M - -
Accounts payable 10.65M 11.56M 11.88M 8.95M 8.85M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 11.28M 3.41M 48.35M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.03M -0.32800M -0.13200M 0.19M 0.25M
Additional paid in capital - - - - -
Common stock total equity - 0.16M 0.15M 0.12M 0.12M
Preferred stock total equity - - - - -
Retained earnings total equity - -1918.14900M -1436.96600M -888.75500M -
Treasury stock - -275.00000M -275.00000M -75.00000M -
Accumulated amortization - - - - -
Non currrent assets other 22.62M 20.22M 33.03M 23.93M -4.85600M
Deferred long term asset charges - - - - -
Non current assets total 68.79M 117.84M 173.08M 60.76M 31.91M
Capital lease obligations 13.11M 15.95M 22.37M 18.47M 8.00M
Long term debt total - 1707.62M 1703.81M 475.86M 91.79M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 453.15M -166.23400M -38.71500M -217.25300M -21.03600M
Change to liabilities 9.82M 22.22M 16.19M -4.65700M 16.70M
Total cashflows from investing activities 453.15M -200.82600M -52.99300M -217.25300M -21.03600M
Net borrowings -20.48600M 1063.61M 536.96M 36.94M 56.34M
Total cash from financing activities -13.13400M 736.45M 447.19M 398.79M 501.55M
Change to operating activities -2.00300M 12.52M 12.82M -3.41300M 5.79M
Net income -484.65200M -586.45400M -505.48800M -288.58500M -169.45100M
Change in cash 20.52M 37.69M -5.51800M -72.04800M 343.87M
Begin period cash flow 396.37M 358.68M 364.20M 436.25M 92.38M
End period cash flow 416.88M 396.37M 358.68M 364.20M 436.25M
Total cash from operating activities -419.49400M -497.93400M -399.71400M -253.58700M -136.64300M
Issuance of capital stock 4.85M 0.00000M 0.00000M 366.24M 430.53M
Depreciation 6.77M 5.84M 3.09M 3.09M 0.24M
Other cashflows from investing activities 115.77M -21.34600M -6.76000M 0.78M 0.78M
Dividends paid - -3.82100M 0.00000M -0.99700M 0.00000M
Change to inventory - - - - -
Change to account receivables 15.17M -19.74900M 2.85M -2.84500M -2.84500M
Sale purchase of stock -1.56100M -204.74600M -75.71400M 368.95M 430.97M
Other cashflows from financing activities 4.06M 1065.31M 521.70M 33.55M 407.11M
Change to netincome 112.72M 111.13M 62.53M 17.91M -28.38500M
Capital expenditures 6.32M 48.25M 7.52M 5.14M 18.18M
Change receivables - - 2.85M - -
Cash flows other operating -72.71600M -56.46700M 6.47M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 20.52M 37.69M -5.51800M - -
Change in working capital 28.08M -4.39600M 14.93M -10.91500M 22.49M
Stock based compensation 91.56M 99.50M 58.46M 21.37M 6.07M
Other non cash items -61.25100M 18.50M 31.16M 24.54M 18.89M
Free cash flow -425.81500M -546.18000M -407.23200M -258.72500M -154.82100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BBIO
BridgeBio Pharma Inc		 -0.31 0.65% 47.38 - - 25.60 123.68 31.71 -9.3955
NVO
Novo Nordisk A/S		 -1.45 2.10% 67.49 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 67.01 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.85 1.66% 464.50 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -18.155 3.18% 552.43 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma Inc

3160 Porter Drive, Palo Alto, CA, United States, 94304

Key Executives

Name Title Year Born
Dr. Neil Kumar Ph.D. Co-Founder, Pres, CEO & Director 1979
Dr. Charles J. Homcy M.D. Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director 1948
Dr. Brian C. Stephenson C.F.A., Ph.D. CFO, Sec. & Principal Accounting Officer 1981
Dr. Richard H. Scheller Ph.D. Chairman of R&D and Director 1953
Dr. Frank McCormick Ph.D. Co-Founder & Chairman of Oncology 1950
Dr. Uma Sinha Ph.D. Chief Scientific Officer 1957
Grace Rauh VP of Communications NA
Mr. Eli M. Wallace Ph.D. Chief Scientific Officer of Oncology 1967
Dr. Thomas Trimarchi Ph.D. Chief Product Officer NA
Dr. Eric Michael David J.D., M.D., Ph.D. Chief Exec. Officer of Gene Therapy 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.